Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-3_05-md-01699/USCOURTS-cand-3_05-md-01699-444/pdf.json

Nature of Suit Code: 365
Nature of Suit: Personal Injury - Product Liability
Cause of Action: 28:1332 Diversity-Product Liability

---

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-1- 

SCHEDULING ORDER RE: (1) MOTS. TO DISMISS SECOND AM. PURCHASE 

CLAIMS MASTER COMPLS.; AND (2) CMC – M:05-CV-01699-CRB 

UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA 

IN RE: BEXTRA AND CELEBREX 

MARKETING SALES PRACTICES AND 

PRODUCT LIABILITY LITIGATION 

CASE NO. M:05-CV-01699-CRB 

MDL No. 1699 

This Order Relates to: 

 ALL CASES. 

SCHEDULING ORDER REGARDING: 

(1) HEARING AND BRIEFING 

SCHEDULE FOR PFIZER’S MOTIONS 

TO DISMISS SECOND AMENDED 

PURCHASE CLAIMS MASTER 

COMPLAINTS; AND 

(2) DATE OF NEXT CASE 

MANAGEMENT CONFERENCE 

1. On Friday, January 5, 2007, the Plaintiffs’ Steering Committee (“PSC”), on 

behalf of all plaintiffs asserting Purchase Claims, filed Second Amended Purchase Claims Master 

Complaints. The Second Amended Purchase Claims Master Bextra Complaint comprises sixtyone pages, while the Second Amended Purchase Claims Master Celebrex Complaint comprises 

one hundred seven pages. 

2. The Pfizer Defendants filed motions to dismiss the Second Amended 

Purchase Claims Master Complaints on Wednesday, January 31, 2007, with briefs comprising 

thirty-five pages in the aggregate. 

///// 

Case 3:05-md-01699-CRB Document 968 Filed 02/02/07 Page 1 of 2
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-2- 

SCHEDULING ORDER RE: (1) MOTS. TO DISMISS SECOND AM. PURCHASE 

CLAIMS MASTER COMPLS.; AND (2) CMC – M:05-CV-01699-CRB 

3. The PSC shall file opposition briefs to the Pfizer Defendants’ motions to 

dismiss the Second Amended Purchase Claims Master Complaints by Friday, March 2, 2007. 

Such briefs shall not exceed thirty-five (35) pages in the aggregate. 

4. The Pfizer Defendants shall file reply briefs in support of their motions to 

dismiss the Second Amended Purchase Claims Master Complaints by Friday, March 16, 2007. 

Such briefs shall not exceed twenty-five (25) pages in the aggregate. 

5. The page limitations set forth herein shall not apply to any signature blocks 

or exhibits submitted in support of the memoranda. Further, the pages may be allocated between 

the briefs directed to the Second Amended Purchase Claims Master Bextra Complaint and those 

directed to the Second Amended Purchase Claims Master Celebrex Complaint as the parties deem 

necessary to state their positions without needless duplication. To the extent arguments apply to 

both Second Amended Master Complaints, those arguments need not be repeated in each brief but 

may be incorporated by reference. 

6. The hearing on Pfizer’s motions to dismiss the Second Amended Purchase 

Claims Master Complaints shall take place at 10:00 a.m. on Friday, April 20, 2007. Pfizer need 

not re-notice the motions. The Court shall hold a case management conference (“CMC”) on 

April 20 immediately following the hearing on the motions. 

7. The CMC and hearing previously scheduled for March 30 (and Pfizer’s 

notice of hearing on April 13) are hereby vacated. 

IT IS SO ORDERED. 

Dated: Feb. 2, 2007 /s/ 

HONORABLE CHARLES R. BREYER 

UNITED STATES DISTRICT JUDGE 

Case 3:05-md-01699-CRB Document 968 Filed 02/02/07 Page 2 of 2